| 04/28/2026 3:15 PM | Fortress Biotech (1429260) Filer | Form DEF 14A | |
| 04/28/2026 3:17 PM | Fortress Biotech (1429260) Filer | Form DEFA14A | |
| 03/31/2026 4:05 PM | Fortress Biotech (1429260) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/20/2026 3:16 PM | Fortress Biotech (1429260) Subject ROSENWALD LINDSAY A MD (941841) Filed by | Form SCHEDULE 13D/A | |
| 03/20/2026 3:05 PM | Fortress Biotech (1429260) Issuer WEISS MICHAEL S (1038977) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/20/2026 3:05 PM | Fortress Biotech (1429260) Issuer ROSENWALD LINDSAY A MD (941841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 7:35 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/13/2026 8:19 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 3:05 PM | AVENUE THERAPEUTICS, INC. (1644963) Issuer Fortress Biotech (1429260) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 4:00 PM | Fortress Biotech (1429260) Filed by MUSTANG BIO, INC. (1680048) Subject | Form SCHEDULE 13D/A | |
| 12/17/2025 11:15 PM | Fortress Biotech (1429260) Filer | Form EFFECT | |
| 12/15/2025 3:33 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/15/2025 7:30 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/17/2025 6:30 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:35 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:46 AM | Fortress Biotech (1429260) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/01/2025 3:05 PM | Fortress Biotech (1429260) Reporting MUSTANG BIO, INC. (1680048) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 3:11 PM | Fortress Biotech (1429260) Filed by MUSTANG BIO, INC. (1680048) Subject | Form SCHEDULE 13D/A | |
| 10/01/2025 7:45 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2025 3:10 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/16/2025 4:25 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2025 7:55 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2025 5:46 PM | Checkpoint Therapeutics, Inc. (1651407) Subject Fortress Biotech (1429260) Filed by | Form SCHEDULE 13D/A | |
| 06/03/2025 5:34 PM | Checkpoint Therapeutics, Inc. (1651407) Issuer Fortress Biotech (1429260) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |